Infections associated with chronic granulomatous disease: Linking genetics to phenotypic expression

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 8, 2012, Pages 881-894

  Ben Ari, Josef ^a   Wolach, Ofir ^b   Gavrieli, Ronit ^c   Wolach, Baruch ^c  

^a MEIR MEDICAL CENTER   (Israel)

^b Davidoff Cancer Center   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

azoles; bone marrow transplantation; chronic granulomatous disease; gene therapy; granulomata; NADPH oxidase; phagocytosis; primary immune deficiency; pyogenic infections; recombinant IFN ; trimethoprim sulfamethoxazole

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; COTRIMOXAZOLE; GAMMA INTERFERON; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERIUM IDENTIFICATION; CHRONIC GRANULOMATOUS DISEASE; CLINICAL FEATURE; FUNGUS IDENTIFICATION; GASTROENTERITIS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; INFECTION COMPLICATION; INFECTION PREVENTION; INFECTION SENSITIVITY; KIDNEY FAILURE; LIVER ABSCESS; LYMPHADENITIS; MELANOMA; MOLECULAR PATHOLOGY; MYCOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; OSTEOMYELITIS; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PHENOTYPIC VARIATION; PHOTOSENSITIVITY; REVIEW; SQUAMOUS CELL CARCINOMA; UNSPECIFIED SIDE EFFECT;

ASPERGILLUS; BACTERIAL INFECTIONS; BONE MARROW TRANSPLANTATION; CATALASE; CHROMOSOMES, HUMAN, X; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; MYCOSES; NADPH OXIDASE; PHENOTYPE; REACTIVE OXYGEN SPECIES; STAPHYLOCOCCUS AUREUS; SURVIVAL ANALYSIS;

EID: 84867077292     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.12.77     Document Type: Review

References (81)

1. Wolach B, Gavrieli R, Roos D, Berger-Achituv S. Lessons learned from phagocytic function studies in a large cohort of patients with recurrent infections. J. Clin. Immunol. 32(3), 454-466 (2012).
2. van den Berg JM, Kuijpers T. Educational paper: defects in number and function of neutrophilic granulocytes causing primary immunodeficiency. Eur. J. Pediatr. 4, 1369-1376 (2011).
3. de Vries E, Driessen G. Educational paper: primary immunodeficiencies in children: a diagnostic challenge. Eur. J. Pediatr. 170(2), 169-177 (2011).
4. Golan H, Dalal I, Garty BZ et al. The incidence of primary immunodeficiency syndromes in Israel. Isr. Med. Assoc. J. 4(11 Suppl.), 868-871 (2002).
5. Janeway CA, Craig J, Davidson M, Downey W, Gitlin D, Sullivan JC. Hypergammaglobulinemia associated with severe, recurrent and chronic non-specific infection. Am. J. Dis. Child. 88, 388-392 (1954).
6. Bridges RA, Berendes H, Good RA. A fatal granulomatous disease of childhood: clinical, pathological and laboratory features of a new syndrome. Am. J. Dis. Child. 97, 387-408 (1959).
7. Kim YM, Park J E, Kim JY et al. Genetic analysis of 10 unrelated Korean families with p22-phox deficient chronic granulomatous disease: an unusually identical mutation of the CYBA gene on Jeju Island, Korea. J. Korean Med. Sci. 24, 1045-1050 (2009).
8. Wolach B, Gavrieli R, de Boer M et al. Chronic granulomatous disease in Israel: clinical, functional and molecular studies of 38 patients. Clin. Immunol. 129(1), 103-114 (2008).
9. van den Berg JM, van Koppen E, Ahlin A et al. Chronic granulomatous disease: the European experience. PLoS ONE 4(4), e5234 (2009).
10. Winkelstein JA, Marino MC, Johnston RB Jr et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 79(3), 155-169 (2000).
11. Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 79(3), 170-200 (2000).
12. Holland SM. Chronic granulomatous disease. Clin. Rev. Allergy Immunol. 38(1), 3-10 (2010).
13. Martire B, Rondelli R, Soresina A et al.; IPINET. Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study. Clin. Immunol. 126(2), 155-164 (2008).
14. Liese J, Kloos S, Jendrossek V et al. Long-term follow-up and outcome of 39 patients with chronic granulomatous disease. J. Pediatr. 137(5), 687-693 (2000).
15. Jones LB, McGrogan P, Flood TJ et al. Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry. Clin. Exp. Immunol. 152(2), 211-218 (2008).
16. Dinauer MC. Disorders of neutrophil function: an overview. Methods Mol. Biol. 412, 489-504 (2007).
17. Segal BH, Veys P, Malech H, Cowan MJ. Chronic granulomatous disease: lessons from a rare disorder. Biol. Blood Marrow Transplant. 17(1 Suppl.), S123-S131 (2011).
18. Stasia MJ, Li XJ. Genetics and immunopathology of chronic granulomatous disease. Semin. Immunopathol. 30(3), 209-235 (2008).
19. Roos D, Kuijpers TW, Curnutte JT. Chronic granulomatous disease. In: Primary Immunodeficiency Diseases, a Molecular and Genetic Approach. Ochs HD, Smith CIE, Puck JM (Eds). Oxford University Press, NY, USA, 525-549 (2007).
20. Kuhns DB, Alvord WG, Heller T et al. Residual NADPH-oxidase and survival in chronic granulomatous disease. N. Engl. J. Med. 363, 2600-2610 (2010).
21. Kuijpers T, Lutter R. Inflammation and repeated infections in CGD: two sides of a coin. Cell. Mol. Life Sci. 69(1), 7-15 (2012).
22. Schäppi MG, Jaquet V, Belli DC, Krause KH. Hyperinflammation in chronic granulomatous disease and antiinflammatory role of the phagocyte NADPH oxidase. Semin. Immunopathol. 30(3), 255-271 (2008).
23. Rieber N, Hector A, Kuijpers T, Roos D, Hartl D. Current concepts of hyperinflammation in chronic granulomatous disease. Clin. Dev. Immunol. 2012, 252460 (2012).
24. De Ravin SS, Naumann N, Cowen EW et al. Chronic granulomatous disease as a risk factor for autoimmune disease. J. Allergy Clin. Immunol. 122(6), 1097-1103 (2008).
25. Parekh C, Hofstra T, Church JA, Coates TD. Hemophagocytic lymphohistiocytosis in children with chronic granulomatous disease. Pediatr. Blood Cancer 56(3), 460-462 (2011).
26. Wolach B, Scharf Y, Gavrieli R, de Boer M, Roos D. Unusual late presentation of X-linked chronic granulomatous disease in an adult female with a somatic mosaic for a novel mutation in CYBB. Blood 105(1), 61-66 (2005).
27. Isman-Nelkenbaum G, Wolach B, Gavrieli R et al. Chronic granulomatous disease of childhood: an unusual cause of recurrent uncommon infections in a 61-year old individual. Clin. Exp. Dermatol. 36, 759-762 (2011).
28. Mueller N. Overview of the epidemiology of malignancy in immune deficiency. J. Acquir. Immune Defic. Syndr. 21(Supp.1), S5-S10 (1999).
29. Wolach B, Ash S, Gavrieli R, Stark B, Yaniv I, Roos D. Acute lymphoblastic leukemia in a patient with chronic granulomatous disease and a novel mutation in CYBB: first report. Am. J. Hematol. 80(1), 50-54 (2005).
30. Weel EA, Redekop WK, Weening RS. Increased risk of malignancy for patients with chronic granulomatous disease and its possible link to the pathogenesis of cancer. Eur. J. Cancer 32A(4), 734-735 (1996).
31. Seger RA. Modern management of chronic granulomatous disease. Br. J. Haematol. 140(3), 255-266 (2008).
32. The International Chronic Granulomatous Disease Cooperative Study Group: a controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N. Engl. J. Med. 324, 509-516 (1991).
33. Bemiller LS, Roberts DH, Starko KM, Curnutte JT. Safety and effectiveness of long-term interferon gamma therapy in patients with chronic granulomatous disease. Blood Cells Mol. Dis. 21(3), 239-247 (1995).
34. Woodman RC, Erickson RW, Rae J, Jaffe HS, Curnutte JT. Prolonged recombinant interferon-gamma therapy in chronic granulomatous disease: evidence against enhanced neutrophil oxidase activity. Blood 79(6), 1558-1562 (1992).
35. Kang EM, Marciano BE, DeRavin S, Zarember KA, Holland SM, Malech HL. Chronic granulomatous disease: overview and hematopoietic stem cell transplantation. J. Allergy Clin. Immunol. 127(6), 1319-1326; quiz 1327 (2011).
36. Seger RA, Gungor T, Belohradsky BH et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. Blood 100(13), 4344-4350 (2002).
37. Soncini E, Slatter MA, Jones LB et al. Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth. Br. J. Haematol. 145(1), 73-83 (2009).
38. Tewari P, Martin PL, Mendizabal A et al. Myeloablative transplantation using either cord blood or bone marrow leads to immune recovery, high long-term donor chimerism and excellent survival in chronic granulomatous disease. Biol. Blood Marrow Transplant. 18(9), 1368-1377 (2012).
39. Grez M, Reichenbach J, Schwable J, Seger R, Dinauer M, Thrasher AJ. Gene therapy for chronic granulomatous disease: the engraftment dilemma. Mol. Therapy 19, 28-35 (2011).
40. Santilli G, Almarza E, Brendel C et al. Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol. Ther. 19(1), 122-132 (2011).
41. Roos D, Kuhns DB, Maddalena A et al. Hematologically important mutations: the autosomal recessive forms of chronic granulomatous disease (second update). Blood Cells Mol. Dis. 44(4), 291-299 (2010).
42. Matute JD, Arias AA, Wright NA et al. A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40 phox and selective defects in neutrophil NADPH oxidase activity. Blood 114(15), 3309-3315 (2009).
43. Fattahi F, Badalzadeh M, Sedighipour L et al. Inheritance pattern and clinical aspects of 93 Iranian patients with chronic granulomatous disease. J. Clin. Immunol. 31(5), 792-801 (2011).
44. Marciano BE, Rosenzweig SD, Kleiner DE et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics 114(2), 462-468 (2004).
45. Wolach B, Broides A, Zeeli T et al. Two X-linked chronic granulomatous disease patients with unusual NADPH-oxidase properties. J. Clin. Immun. 31, 560-566 (2011).
46. Stasia MJ, Lardy B, Maturana A et al. Molecular and functional characterization of a new X-linked chronic granulomatous disease variant (X91+) case with a double missense mutation in the gp91-phox cytosolic C-terminal tail. Biochim. Biophys. Acta. 1586, 316-330 (2002).
47. Bylund J, Brown KL, Movitz C, Dahlgren C, Karlsson A. Intracellular generation of superoxide by the phagocyte NADPH oxidase: how, where, and what for? Free Radic. Biol. Med. 49(12), 1834-1845 (2010).
48. Guide SV, Stock F, Gill VJ et al. Reinfection rather than persistent infection, in patients with chronic granulomatous disease. J. Infect. Dis. 187, 845-853 (2003).
49. Lee PP, Chan KW, Jiang L et al. Susceptibility to mycobacterial infections in children with X-linked chronic granulomatous disease: a review of 17 patients living in a region endemic for tuberculosis. Pediatr. Infect. Dis. J. 27(3), 224-230 (2008).
50. Martín A, Marques L, Soler-Palacín P et al. Viceral leishmaniasis associated hemophagocytic syndrome in patients with chronic granulomatous disease. Pediatr. Infect. Dis. J. 28(8), 753-754 (2009).
51. Lyratzopoulos G, Ellis M, Nerringer R, Denning DW. Invasive infection due to penicillium species other than P. marneffei. J. Infect. 45(3), 184-195 (2002).
52. Beaute J, Obenga G, Le Mignot L et al. Epidemiology and outcome of invasive fungal diseases in patients with chronic granulomatous disease: a multicenter study in France. Pediatr. Infect. Dis. J. 30, 57-62 (2011).
53. Blumental S, Mouy R, Mahlahoui N et al. Invasive mold infections in chronic granulomatous disease: a 25 year retrospective survey. Clin. Infect. Dis. 53(12), e159-e169 (2011).
54. Segal B, Romani LR. Invasive aspergillosis in chronic granulomatous disease. Med. Mycol. 18, 51-59 (2009).
55. Vinh DC, Shea YR, Jones PA, Freeman AF, Zelazny A, Holland SM. Chronic invasive aspergillosis caused by Aspergillus viridinutans. Emerging Infect. Dis. 15(8), 1292-1294 (2009).
56. Segal BH, Barnhart LA, Anderson VL, Walsh TJ, Malech HL, Holland SM. Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin. Infect. Dis. 40(11), 1684-1688 (2005).
57. Van Der Linden JW, Warris A, Verweij PE. Aspergillus species intrinsically resistant to antifungal agents. Med. Mycol. 49(Suppl. 1), S82-S89 (2011).
58. Seger RA. Advances in the diagnosis and treatment of chronic granulomatous disease. Curr. Opin. Hematol. 18, 36-41 (2011).
59. Yamazaki-Nakashimada MA, Stiehm ER, Pietropaolo-Cienfuegos D, Hernandez-Bautista V, Espinosa-Rosales F. Corticosteroid therapy for refractory infections in chronic granulomatous disease: case reports and review of the literature. Ann. Allergy Asthma Immunol. 97(2), 257-261 (2006).
60. Reichenbach J, Lopatin U, Mahlaoui N et al. Actinomyces in chronic granulomatous disease: an emerging and unanticipated pathogen. Clin. Infect. Dis. 49(11), 1703-1710 (2009).
61. Smego RA Jr, Gallis HA. The clinical spectrum of Nocardia brasilensis infection in the United States. Rev. Infect. Dis. 6, 164-180 (1984).
62. Frumkin A. Nocardial infections in Israel: a survey. Isr. J. Med. Sci. 25(6), 324-327 (1989).
63. Greenberg DE, Goldberg JB, Stock F, Murray PR, Holland SM, Lipuma JJ. Recurrent Burkholderia infection in patients with chronic granulomatous disease: 11-year experience at a large referral center. Clin. Infect. Dis. 48(11), 1577-1579 (2009).
64. Ameratunga R, Woon ST, Vyas J, Roberts S. Fulminant mulch pneumonitis in undiagnosed chronic granulomatous disease: a medical emergency. Clin. Pediatr. (Phil.) 49(12), 1143-1146 (2010).
65. Siddiqui S, Anderson VL, Hilligoss DM et al. Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous disease. Clin. Infect. Dis. 45(6), 673-681 (2007).
66. Pogrebniak HW, Gallin JI, Malech HL et al. Surgical management of pulmonary infections in chronic granulomatous disease of childhood. Ann. Thorac. Surg. 55(4), 844-849 (1993).
67. Greenberg DE, Ding L, Zelazny AM et al. A novel bacterium associated with lymphadenitis in a patient with chronic granulomatous disease. PLoS Pathog. 2(4), e28 (2006).
68. Greenberg DE, Shoffner AR, Zelazny AM et al. Recurrent Granulibacter bethesdensis infections and chronic granulomatous disease. Emerging Infect. Dis. 16(9), 1341-1348 (2010).
69. Lublin M, Bartlett DL, Danforth DN et al. Hepatic abscess in patients with chronic granulomatous disease. Ann. Surg. 235(3), 383-391 (2002).
70. Towbin AJ, Chaves I. Chronic granulomatous disease. Pediatr. Radiol. 40(5), 657-668; quiz 792 (2010).
71. Leiding JW, Freeman AF, Marciano BE et al. Corticosteroid therapy for liver abscess in chronic granulomatous disease. Clin. Infect. Dis. 54(5), 694-700 (2012).
72. Dotis J, Roilides E. Osteomyelitis due to Aspergillus species in chronic granulomatous disease: an update of the literature. Mycoses 54(6), e686-e696 (2011).
73. Margolis DM, Melnick DA, Alling DW, Gallin JI. Trimethoprim- sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J. Infect. Dis. 162(3), 723-726 (1990).
74. Gallin JI, Alling DW, Malech AL et al. Itraconazole prophylaxis for fungal infections in chronic granulomatous disease of childhood. N. Engl. J. Med. 348, 2416-2422 (2003).
75. Cowen EW, Nguyen JC, Miller DD et al. Chronic phototoxicity and agrresive Squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J. Am. Acad. Dermatol. 62, 31-37 (2010).
76. Miller DD, Cowen EW, Nguyen JC, McCalmont TH, Fox LP. Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch. Dermatol. 146, 300-304 (2010).
77. Rozenzweig SD. Inflammatory manifestations in chronic granulomatous disease (CGD). J. Clin. Immunol. 28, S67-S72 (2008).
78. Feld JJ, Hussain N, Wright EC et al. Hepatic involvement and portal hypertension predict mortality in chronic granulomatous disease. Gastroenterology 134(7), 1917-1926 (2008).
79. Marks DJ, Miyagi K, Rahman FZ, Novelli M, Bloom SL, Segal AW. Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn's disease. Am. J. Gastroenterol. 104(1), 117-124 (2009).
80. Jürgens B, Fuchs D, Reichenbach J, Heitger A. Intact indoleamine 2,3-dioxygenase activity in human chronic granulomatous disease. Clin. Immunol. 137(1), 1-4 (2010).
81. Meissner F, Seger RA, Moshous D, Fischer A, Reichenbach J, Zychlinsky A. Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous disease. Blood 116(9), 1570-1573 (2010).